amiodarone HCl

amiodarone HCl (əmē´ōdərōn´),

n brand name: Cordarone;
drug class: antidysrhythmic (drug class III);
action: prolongs action potential duration and effective refractory period;
uses: documented life-threatening ventricular tachycardia.
References in periodicals archive ?
2001: Ligand (formerly CyDex Pharmaceuticals) began development of Captisol-enabled formulation of Amiodarone HCL.
CyDex has provided Prism Pharmaceuticals with technical support since they first licensed the worldwide rights to a Captisol-enabled([R]) amiodarone HCL formulation from us in 2006," said Theron E.
2g, Inj Heparin Low Molecular weight of 10ml, Acenocounmarol Tab 4mg, Tab Levodopa 250 mg with Carvidopa 25 mg, Inj Tranexamic acid 500 mg 5 m, Tab Tranexamic acid 500 mg, Tab Diltiazem 60 mg, Tab Diltazem 90 mg Controlled Delivery, Esmolol 100 mg 10 ml, Tab Fenofibrate 200 mg, Tab Isosorbide 5 Mononitrate 20 mg, Tab Nicorandil 10 mg, Tab Nifedepine 10 mg, Inj Nitroglycerine 5 mg, Simvastatin 20 mg, Amiodarone Hcl 200 mg, Lignocaine Hcl solution 2% for I V 50 ml, Propranolol 40 mg, Digoxin 0.
a privately-held specialty pharmaceutical company, today announced that it has launched amiodarone HCl injection, USP, a class III antiarrhythmic indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia -- a potentially life-threatening irregular heart beat.
Amiodarone HCl Injection, USP, is a class III antiarrhythmic indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.
CGTH036 10/04/2001 14:47 r f bc-CA-APP-FDA-approval (LOS ANGELES) APP is the First to Receive a Tentative Approval on Amiodarone HCl, Injection, USP
APP's Amiodarone HCl Injection, USP should be available once the innovator's product patent reaches expiry.
Food and Drug Administration (FDA), Wyeth-Ayerst requested the immediate withdrawal of the current protocol review package for generic amiodarone HCl tablets, citing inadequate testing criteria to establish bioequivalence.